Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies

Journal of Pharmacological Sciences

Volumn 138, Issue 4, 2018, Pages 219-232

  Bucolo, Claudio ^a   Gozzo, Lucia ^b   Longo, Laura ^b   Mansueto, Silvana ^b   Vitale, Daniela Cristina ^b   Drago, Filippo ^a,b  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Dexamethasone; Diabetic macular edema; Intravitreal implant; Ocular drug delivery; Systematic review

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; HEMOGLOBIN A1C; RANIBIZUMAB; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

ADVERSE OUTCOME; APHAKIA; CATARACT; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CHEMOSIS; CONJUNCTIVAL HEMORRHAGE; DIABETIC MACULAR EDEMA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENDOPHTHALMITIS; EYE INFECTION; EYE INJURY; FOLLOW UP; HUMAN; INCIDENCE; INFORMED CONSENT; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE ABNORMALITY; LONG TERM CARE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PEER REVIEW; PUNCTATE KERATITIS; RETINA FLUORESCEIN ANGIOGRAPHY; RETINAL THICKNESS; RETREATMENT; REVIEW; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMATIC REVIEW; TREATMENT DURATION; DIABETIC RETINOPATHY; DRUG IMPLANT; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; DEXAMETHASONE; DIABETIC RETINOPATHY; DRUG IMPLANTS; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; TREATMENT OUTCOME;

EID: 85057376923     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2018.11.001     Document Type: Review

References (49)

1. Fong, D.S., Aiello, L.P., Ferris, F.L. 3rd, Klein, R., Diabetic retinopathy. Diabetes Care 27 (2004), 2540–2553.
2. Williams, R., Airey, M., Baxter, H., et al. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond)2 18 (2004), 963–983.
3. Narayan, K.M., Boyle, J.P., Geiss, L.S., et al. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care 29 (2006), 2114–2116.
4. Stewart, M.W., Flynn, H.W. Jr., Schwartz, S.G., Scott, I.U., Extended duration strategies for the pharmacologic treatment of diabetic retinopathy: current status and future prospects. Expert Opin Drug Deliv 13 (2016), 1277–1287.
5. Gardner, T.W., Antonetti, D.A., Novel potential mechanisms for diabetic macular edema: leveraging new investigational approaches. Curr Diabetes Rep 8 (2008), 263–269.
6. Averbukh, E., Banin, E., Diabetic macular edema: towards therapy aimed at the underlying pathogenic mechanisms. Isr Med Assoc J 8 (2006), 127–128.
7. Qian, T.W., Zhao, M.Y., Li, X.X., Xu, X., Efficiency and safety of laser photocoagulation with or without intravitreal ranibizumab for treatment of diabetic macular edema: a systematic review and meta-analysis. Int J Ophthalmol 10 (2017), 1134–1143.
8. Wu, Y., Ai, P., Ai, Z., Xu, G., Subthreshold diode micropulse laser versus conventional laser photocoagulation monotherapy or combined with anti-VEGF therapy for diabetic macular edema: a Bayesian network meta-analysis. Biomed Pharmacother 97 (2017), 293–299.
9. Zhang, X., Wang, N., Schachat, A.P., et al. Glucocorticoids: structure, signaling and molecular mechanisms in the treatment of diabetic retinopathy and diabetic macular edema. Curr Mol Med 14 (2014), 376–384.
10. Sohn, H.J., Han, D.H., Kim, I.T., et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 152 (2011), 686–694.
11. Vujosevic, S., Torresin, T., Bini, S., et al. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema. Acta Ophthalmol 95 (2017), 464–471.
12. Ciulla, T.A., Walker, J.D., Fong, D.S., Criswell, M.H., Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15 (2004), 211–220.
13. Ciulla, T.A., Harris, A., McIntyre, N., Jonescu-Cuypers, C., Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother 15 (2014), 953–959.
14. Khan, Z., Kuriakose, R.K., Khan, M., et al. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina 48 (2017), 160–166.
15. Haller, J.A., Dugel, P., Weinberg, D.V., et al. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29 (2009), 46–51.
16. Boyer, D.S., Yoon, Y.H., Belfort, R. Jr., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121 (2014), 1904–1914.
17. Sarao, V., Veritti, D., Furino, C., et al. Dexamethasone implant with fixed or individualized regimen in the treatment of diabetic macular oedema: six-month outcomes of the UDBASA study. Acta Ophthalmol 95 (2017), e255–e260.
18. Querques, G., Darvizeh, F., Querques, L., et al. Assessment of the real-life usage of intravitreal dexamethasone implant in the treatment of chronic diabetic macular edema in France. J Ocul Pharmacol Ther 32 (2016), 383–389.
19. Slim, K., Nini, E., Forestier, D., et al. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg 73 (2003), 712–716.
20. Guyatt, G.H., Oxman, A.D., Vist, G., et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 64 (2011), 407–415.
21. Guigou, S., Pommier, S., Meyer, F., et al. Efficacy and safety of intravitreal dexamethasone implant in patients with diabetic macular edema. Ophthalmologica 233 (2015), 169–175.
22. Malcles, A., Dot, C., Voirin, N., et al. Safety of intravitreal dexamethasone implant (Ozurdex): the SAFODEX study. Incidence and risk factors of ocular hypertension. Retina 37 (2017), 1352–1359.
23. Pacella, E., Vestri, A.R., Muscella, R., et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clin Ophthalmol 7 (2013), 1423–1428.
24. Escobar-Barranco, J.J., Pina-Marin, B., Fernandez-Bonet, M., Dexamethasone implants in patients with naive or refractory diffuse diabetic macular edema. Ophthalmologica 233 (2015), 176–185.
25. Lam, W.C., Albiani, D.A., Yoganathan, P., et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 9 (2015), 1255–1268.
26. Mastropasqua, R., Toto, L., Borrelli, E., et al. Morphology and function over a one-year follow up period after intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema. PLoS One, 10, 2015, e0145663.
27. Panozzo, G., Gusson, E., Panozzo, G., Dalla Mura, G., Dexamethasone intravitreal implant for diabetic macular edema: indications for a PRN regimen of treatment. Eur J Ophthalmol 25 (2015), 347–351.
28. Scaramuzzi, M., Querques, G., Spina, C.L., et al. Repeated intravitreal dexamethasone implant (Ozurdex) for diabetic macular edema. Retina 35 (2015), 1216–1222.
29. Aknin, I., Melki, L., Longitudinal study of sustained-release dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmologica 235 (2016), 187–188.
30. Bansal, P., Gupta, V., Gupta, A., et al. Efficacy of Ozurdex implant in recalcitrant diabetic macular edema—a single-center experience. Int Ophthalmol 36 (2016), 207–216.
31. Chhablani, J., Bansal, P., Veritti, D., et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond) 30 (2016), 426–430.
32. Matonti, F., Pommier, S., Meyer, F., et al. Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol 26 (2016), 454–459.
33. Moon, B.G., Lee, J.Y., Yu, H.G., et al. Efficacy and safety of a dexamethasone implant in patients with diabetic macular edema at tertiary centers in Korea. J Ophthalmol, 2016, 2016, 9810270.
34. Ozkaya, A., Alagoz, C., Alagoz, N., et al. Dexamethasone implant in pseudophakic and nonglaucomatous subgroup of diabetic macular edema patients: a real life experience. Eur J Ophthalmol 26 (2016), 351–355.
35. Pacella, F., Ferraresi, A.F., Turchetti, P., et al. Intravitreal injection of ozurdex implant in patients with persistent diabetic macular edema, with six-month follow-up. Ophthalmol Eye Dis 8 (2016), 11–16.
36. Pacella, F., Romano, M.R., Turchetti, P., et al. An eighteen-month follow-up study on the effects of intravitreal dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 9 (2016), 1427–1432.
37. Arikan Yorgun, M., Toklu, Y., Mutlu, M., Comparison of early dexamethasone retreatment versus standard dexamethasone regimen combined with PRN ranibizumab in diabetic macular edema. Int Ophthalmol 37 (2017), 185–196.
38. Cicinelli, M.V., Cavalleri, M., Querques, L., et al. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema. Br J Ophthalmol 101 (2017), 1689–1693.
39. Esen, E., Sizmaz, S., Demircan, N., Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema. Int Ophthalmol 37 (2017), 1–6.
40. Malcles, A., Dot, C., Voirin, N., et al. Real-life study in diabetic macular edema treated with dexamethasone implant: the Reldex study. Retina 37 (2017), 753–760.
41. Sacconi, R., Battaglia Parodi, M., Casati, S., et al. Dexamethasone implants in diabetic macular edema patients with high visual acuity. Ophthalmic Res 58 (2017), 125–130.
42. Unsal, E., Eltutar, K., Sultan, P., et al. Efficacy and safety of intravitreal dexamethasone implants for treatment of refractory diabetic macular edema. Korean J Ophthalmol 31 (2017), 115–122.
43. Zandi, S., Lereuil, T., Freiberg, F., et al. Long-term intravitreal dexamethasone treatment in eyes with pretreated chronic diabetic macular edema. J Ocul Pharmacol Ther 33 (2017), 620–628.
44. Callanan, D.G., Loewenstein, A., Patel, S.S., et al. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255 (2017), 463–473.
45. Shah, S.U., Harless, A., Bleau, L., Maturi, R.K., Prospective randomized subject-masked study of intravitreal bevacizumab monotherapy versus dexamethasone implant monotherapy in the treatment of persistent diabetic macular edema. Retina 36 (2016), 1986–1996.
46. Gillies, M.C., Lim, L.L., Campain, A., et al. A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121 (2014), 2473–2481.
47. Maturi, R.K., Pollack, A., Uy, H.S., et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year mead study. Retina 36 (2016), 1143–1152.
48. Bucolo, C., Campana, G., Di Toro, R., Cacciaguerra, S., Spampinato, S., Sigma1 recognition sites in rabbit iris-ciliary body: topical sigma1-site agonists lower intraocular pressure. J Pharmacol Exp Ther 289:3 (1999 Jun), 1362–1369.
49. Shafiee, A., Bucolo, C., Budzynski, E., Ward, K.W., López, F.J., In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 52:3 (2011 Mar 14), 1422–1430.